The purposes of Biospecimens Accessioning and Processing (BAP) Shared Resource are 1) to provide a central facility to electronically accession biospecimens intended for cancer research, 2) to process the specimens appropriately according to their projected end use, 3) to provide nucleic acid extraction services, and 4) to provide cryopreservation of mononuclear cells and EBV immortalization of B lymphocytes. Specimens accessioned in the shared resource will be linked to the Mayo Life Sciences Warehouse database, so that each specimen will be associated with patient data under Internal Review Board-approved protocols. When appropriate, accessioning also will be linked to the specimen tracking database for storage in a central warehouse freezer. Biospecimens accessioned through this resource include solid tissues as well as whole blood and other bodily fluids. Once accessioned, blood specimens will be processed for nucleic acid extraction, future or immediate EBV immortalization of mononuclear cells, and/or frozen storage as plasma, serum or buffy coats. Other fluids will be aliquoted and stored frozen for future analyses, including proteomics and pharmacokinetics. Fresh solid tissues will be dissected and flash frozen in liquid nitrogen or placed in molds containing freezing medium prior to freezing in a controlled temperature histobath. One of the most valuable contributions of the BAP resource is the specimen annotation that is brought into the Research Biospecimen Database at the time of specimen accessioning. Together, the electronic biospecimen accessioning combined with basic specimen processing, EBV immortalization, and nucleic acid extraction services have created a very powerful, synergistic Shared Resource invaluable for supporting the translational, epidemiologic, and basic research programs for Cancer Center members. Future objectives for this shared resource include 1) developing strategies to routinely collect tissues from all three Mayo sites for future RNA extraction without compromising histology and immunohistochemistry, and 2) expanding to all three Mayo sites the electronic accessioning of specimens into a central Research Biospecimen Database. This collection of biospecimens will allow us to build a unique, valuable resource of highly annotated specimens to support cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-30
Application #
6990015
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-09-15
Project End
2009-02-28
Budget Start
2004-09-15
Budget End
2005-02-28
Support Year
30
Fiscal Year
2004
Total Cost
$150,068
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7

Showing the most recent 10 out of 1129 publications